OK-432 therapy for lymphangiomas.
To assess the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas. Nonrandomized trial; follow-up, 4 to 29 months. Academic tertiary referral medical center. Six children with presumed lymphangiomas; age range at initial treatment, 1 month to 7 years 10 months. Fluoroscopically guided cyst aspiration, cystography, and injection of OK-432. Clinical and radiographic comparisons before and after therapy. Complete response in 2 macrocystic lymphangiomas; no response in 3 microcystic lymphangiomas; and no response in 1 venous malformation. OK-432 sclerotherapy may be effective treatment for macrocystic lymphangiomas.